Dane Leone
Stock Analyst at Raymond James
(1.14)
# 3,648
Out of 4,944 analysts
69
Total ratings
33.96%
Success rate
-9.71%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $3.42 | +455.56% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.71 | +459.68% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $8.93 | +403.92% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $36.07 | -16.83% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $561.55 | +69.17% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.21 | +488.24% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $50.38 | -8.69% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $32.31 | +113.56% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $3.10 | +158.06% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $12.50 | +12.00% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $7.72 | +651.30% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $14.53 | +381.76% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.04 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $36.88 | +70.82% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $47.85 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.72 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $52.72 | +23.29% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $289.33 | -11.87% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $3.65 | +776.71% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $174.42 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $3.42
Upside: +455.56%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.71
Upside: +459.68%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $8.93
Upside: +403.92%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $36.07
Upside: -16.83%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $561.55
Upside: +69.17%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.21
Upside: +488.24%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $50.38
Upside: -8.69%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $32.31
Upside: +113.56%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $3.10
Upside: +158.06%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $12.50
Upside: +12.00%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $7.72
Upside: +651.30%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $14.53
Upside: +381.76%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.04
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $36.88
Upside: +70.82%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $47.85
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.72
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $52.72
Upside: +23.29%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $289.33
Upside: -11.87%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $3.65
Upside: +776.71%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $174.42
Upside: -